Sphingolipid profiling as a biomarker of type 2 diabetes risk: evidence from the MIDUS and PREDIMED studies

• Published in: Cardiovascular diabetology 2024-12, Vol.23 (1), p.446-13
• Main Authors: Berkowitz, Loni, Razquin, Cristina, Salazar, Cristian, Biancardi, Fiorella, Estruch, Ramón, Ros, Emilio, Fitó, Montserrat, Corella, Dolores, Coe, Christopher L, Ryff, Carol D, Ruiz-Canela, Miguel, Salas-Salvado, Jordi, Wang, Daniel, Hu, Frank B, Deik, Amy, Martínez-Gonzalez, Miguel A, Rigotti, Attilio
• Format: Article
• Language: English
• Subjects: Aged; Aged, 80 and over; Biomarkers - blood; Ceramides; Ceramides - blood; Cross-Sectional Studies; Diabetes Mellitus, Type 2 - blood; Diabetes Mellitus, Type 2 - diagnosis; Diabetes Mellitus, Type 2 - epidemiology; Female; Humans; Incidence; Insulin Resistance; Lactosylceramides; Lipidomics; Male; Middle Aged; Predictive Value of Tests; Prevalence; Prospective Studies; Risk Assessment; Risk Factors; Sphingolipids; Sphingolipids - blood; Time Factors; Type 2 diabetes; United States - epidemiology
• ISSN: 1475-2840; 1475-2840
• DOI: 10.1186/s12933-024-02505-7

Type 2 diabetes (T2D) has become a worldwide pandemic. While ceramides may serve as intermediary between obesity-related lipotoxicity and T2D, the relationship with simple glycosphingolipids remains uncertain. The aim of this study was to characterize the associations between blood glycosphingolipid and ceramide species with T2D and to identify a circulating sphingolipid profile that could serve as novel biomarker for T2D risk. Cross-sectional relationship between sphingolipid levels, insulin resistance, and T2D prevalence were evaluated in 2,072 American adults from MIDUS cohort. Prospectively, the association between sphingolipid species and the incidence of T2D was analyzed using a case-cohort design nested within the PREDIMED trial (250 cases and a random sample of 692 participants, with 3.8 years of median follow-up). Circulating levels of sphingolipid species in both populations were measured using LC/MS. Hazard ratios were estimated with weighted Cox regression models using Barlow weights. In American adults, only CER18:0 and CER22:0 were linked to insulin resistance and a higher prevalence of T2D. Conversely, three lactosylceramides (LCER 14:0, 16:0, and 24:1) showed a strong inverse relationship with both insulin resistance and T2D. These findings led to development of two sphingolipid scores. In the prospective analysis, these scores consistently predicted a reduced risk of T2D incidence in PREDIMED (HR: 0.64, 95% CI 0.44 to 0.94 and 0.58, 0.40 to 0.85 respectively) between extreme quartiles, with 5-year absolute risk differences of 9.6% (95% CI: 0.3-20.5%) and 11.4% (1.0-21.6%). They were validated in the same trial with samples obtained after 1 year of follow-up. Our findings support the potential usefulness of circulating sphingolipid profiles as novel biomarkers for T2D risk. Moreover, this study opens the door for future research on the predictive value and possible protective roles of lactosylceramides in T2D.